Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
43
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Smith Justin Adam | Director | 10 | $202.4K | $0 | 2026-07-01 |
| Toledano Miranda Jayne | Director | 8 | $0 | $0 | 2026-07-01 |
| Herskowitz Neil | Director | 8 | $0 | $0 | 2026-07-01 |
| ROSENWALD LINDSAY A MD | Director | 8 | $321.4K | $0 | 2026-06-25 |
| Pearce Michael Cooper | Director | 4 | $0 | $0 | 2026-06-25 |
| Alloush Ramsey | Chief Operating Officer | 5 | $0 | $19.5K | 2026-04-22 |
| Maraoui Claude | President & CEO | 22 | $100.4K | $938.3K | 2026-04-22 |
| Benesch Joseph | See Remarks | 13 | $0 | $118.3K | 2026-04-22 |
| Paley Jeffrey | Director | 8 | $133.8K | $17.9K | 2023-11-28 |
| Fortress Biotech, Inc. | 10% Owner | 5 | $0 | $0 | 2023-05-12 |
| De Paolantonio Ernest Robert | See Remarks | 4 | $0 | $48.6K | 2022-10-04 |
| ELI LILLY & Co | 10% Owner | 1 | $767.36M | $0 | 2020-02-20 |
| Aurora Daljit Singh | Chief Scientific Affairs Off | 16 | $0 | $0 | 2020-02-20 |
| Horan Christopher | Chief Technical Ops Officer | 12 | $0 | $0 | 2020-02-20 |
| Lyons-Williams Lori | Chief Commercial Officer | 22 | $0 | $0 | 2020-02-20 |
| Sebelius Kathleen | Director | 19 | $0 | $0 | 2020-02-20 |
| Pena Luis C. | EVP Product Development | 69 | $0 | $794.8K | 2020-02-20 |
| Griffith Christopher M. | VP Corp. Dev. & Strategy | 134 | $0 | $1.09M | 2020-02-20 |
| Gilbert Halley E | Director | 2 | $0 | $0 | 2020-02-20 |
| Nunn Jason Raleigh | Director | 20 | $0 | $0 | 2020-02-20 |
| Fust Matthew K | Director | 27 | $100.6K | $188.6K | 2020-02-20 |
| Cohen David E | Director | 30 | $0 | $125.7K | 2020-02-20 |
| MCDADE MARK | Director | 21 | $0 | $0 | 2020-02-20 |
| RINGO WILLIAM R | Director | 54 | $0 | $165.7K | 2020-02-20 |
| GUGGENHIME ANDREW | COO and CFO | 73 | $0 | $1.98M | 2020-02-20 |
| BAUER EUGENE A | Chief Medical Officer | 115 | $0 | $3.09M | 2020-02-20 |
| WIGGANS THOMAS G | CEO & Chairman of the Board | 139 | $679.5K | $6.01M | 2020-02-20 |
| CRAVES FRED B | Director, 10% Owner | 34 | $1.80M | $0 | 2020-02-20 |
| Canaan Partners VIII LLC | Director, 10% Owner | 2 | $0 | $0 | 2015-11-30 |
| Hutton Wende S | Director | 6 | $788.4K | $0 | 2015-06-11 |
| Viswanathan Ravi | 10% Owner | 5 | $1.11M | $0 | 2014-10-08 |
| NEW ENTERPRISE ASSOCIATES 13 LP | 10% Owner | 5 | $1.11M | $0 | 2014-10-08 |
| Canaan VIII LP | Director, 10% Owner | 5 | $788.4K | $0 | 2014-10-08 |
| Bay City Capital Fund V, L.P. | 10% Owner | 10 | $1.11M | $0 | 2014-10-08 |
| Weller Harry R | 10% Owner | 5 | $1.11M | $0 | 2014-10-08 |
| DRANT RYAN D | 10% Owner | 5 | $1.11M | $0 | 2014-10-08 |
| BASKETT FOREST | 10% Owner | 5 | $1.11M | $0 | 2014-10-08 |
| KOLLURI KRISHNA KITTU | 10% Owner | 5 | $1.11M | $0 | 2014-10-08 |
| SANDELL SCOTT D | 10% Owner | 5 | $1.11M | $0 | 2014-10-08 |
| KERINS PATRICK J | 10% Owner | 5 | $1.11M | $0 | 2014-10-08 |
| MOTT DAVID M | 10% Owner | 5 | $1.11M | $0 | 2014-10-08 |
| BARRETT M JAMES | 10% Owner | 5 | $1.11M | $0 | 2014-10-08 |
| BARRIS PETER J | 10% Owner | 5 | $1.11M | $0 | 2014-10-08 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Herskowitz Neil | Director | A Award | 2026-07-01 | 2026-07-02 | 50,000 | — | $0 | 168,618 | SEC↗ |
| Smith Justin Adam | Director | A Award | 2026-07-01 | 2026-07-02 | 50,000 | — | $0 | 231,618 | SEC↗ |
| Toledano Miranda Jayne | Director | A Award | 2026-07-01 | 2026-07-02 | 50,000 | — | $0 | 168,618 | SEC↗ |
| ROSENWALD LINDSAY A MD | Director | A Award | 2026-06-25 | 2026-06-26 | 10,000 | — | $0 | 221,146 | SEC↗ |
| Pearce Michael Cooper | Director | A Award | 2026-06-25 | 2026-06-26 | 10,000 | — | $0 | 67,173 | SEC↗ |
| Herskowitz Neil | Director | A Award | 2026-06-25 | 2026-06-26 | 10,000 | — | $0 | 118,618 | SEC↗ |
| Smith Justin Adam | Director | A Award | 2026-06-25 | 2026-06-26 | 10,000 | — | $0 | 181,618 | SEC↗ |
| Toledano Miranda Jayne | Director | A Award | 2026-06-25 | 2026-06-29 | 10,000 | — | $0 | 118,618 | SEC↗ |
| Maraoui Claude | President & CEO | A Award deriv | 2026-04-22 | 2026-04-24 | 82,915 | — | $0 | 82,915 | SEC↗ |
| Benesch Joseph | CFO | A Award deriv | 2026-04-22 | 2026-04-24 | 41,860 | — | $0 | 41,860 | SEC↗ |
| Alloush Ramsey | Chief Operating Officer | A Award deriv | 2026-04-22 | 2026-04-24 | 62,795 | — | $0 | 62,795 | SEC↗ |
| Maraoui Claude | President & CEO | A Award | 2026-04-22 | 2026-04-24 | 49,277 | — | $0 | 2,435,990 | SEC↗ |
| Benesch Joseph | CFO | A Award | 2026-04-22 | 2026-04-24 | 28,907 | — | $0 | 261,371 | SEC↗ |
| Alloush Ramsey | Chief Operating Officer | A Award | 2026-04-22 | 2026-04-24 | 46,863 | — | $0 | 598,543 | SEC↗ |
| Maraoui Claude | President & CEO | M Exercise deriv | 2025-08-25 | 2025-08-26 | 1,250,000 | — | $0 | 0 | SEC↗ |
| Maraoui Claude | President & CEO | F Tax w/h | 2025-08-25 | 2025-08-26 | 10,877 | $7.47 | $81.3K | 2,386,713 | SEC↗ |
| Maraoui Claude | President & CEO | M Exercise | 2025-08-25 | 2025-08-26 | 1,250,000 | $0.07 | $87.5K | 2,397,590 | SEC↗ |
| Herskowitz Neil | Director | A Award | 2025-08-05 | 2025-08-07 | 20,000 | — | $0 | 108,618 | SEC↗ |
| Pearce Michael Cooper | Director | A Award | 2025-08-05 | 2025-08-07 | 20,000 | — | $0 | 57,173 | SEC↗ |
| Toledano Miranda Jayne | Director | A Award | 2025-08-05 | 2025-08-07 | 20,000 | — | $0 | 108,618 | SEC↗ |
| Smith Justin Adam | Director | A Award | 2025-08-05 | 2025-08-07 | 20,000 | — | $0 | 171,618 | SEC↗ |
| ROSENWALD LINDSAY A MD | Director | A Award | 2025-08-05 | 2025-08-07 | 50,000 | — | $0 | 211,146 | SEC↗ |
| Herskowitz Neil | Director | A Award | 2025-06-25 | 2025-07-07 | 7,173 | — | $0 | 88,618 | SEC↗ |
| Smith Justin Adam | Director | A Award | 2025-06-25 | 2025-07-07 | 7,173 | — | $0 | 151,618 | SEC↗ |
| Pearce Michael Cooper | Director | A Award | 2025-06-25 | 2025-07-07 | 7,173 | — | $0 | 37,173 | SEC↗ |
| ROSENWALD LINDSAY A MD | Director | A Award | 2025-06-25 | 2025-07-07 | 7,173 | — | $0 | 161,146 | SEC↗ |
| Toledano Miranda Jayne | Director | A Award | 2025-06-25 | 2025-07-07 | 7,173 | — | $0 | 88,618 | SEC↗ |
| Maraoui Claude | President & CEO | A Award deriv | 2025-06-17 | 2025-06-20 | 82,915 | — | $0 | 82,915 | SEC↗ |
| Benesch Joseph | CFO | A Award deriv | 2025-06-17 | 2025-06-20 | 41,860 | — | $0 | 41,860 | SEC↗ |
| Alloush Ramsey | Chief Operating Officer | A Award deriv | 2025-06-17 | 2025-06-20 | 62,795 | — | $0 | 62,795 | SEC↗ |
| Maraoui Claude | President & CEO | A Award | 2025-06-17 | 2025-06-20 | 49,277 | — | $0 | 2,397,590 | SEC↗ |
| Benesch Joseph | CFO | A Award | 2025-06-17 | 2025-06-20 | 28,907 | — | $0 | 232,464 | SEC↗ |
| Alloush Ramsey | Chief Operating Officer | A Award | 2025-06-17 | 2025-06-20 | 46,863 | — | $0 | 551,680 | SEC↗ |
| Alloush Ramsey | COO | S Sale | 2025-05-02 | 2025-05-05 | 2,857 | $6.84 | $19.5K | 504,817 | SEC↗ |
| Benesch Joseph | CFO | S Sale | 2025-05-02 | 2025-05-05 | 2,409 | $6.84 | $16.5K | 203,557 | SEC↗ |
| Maraoui Claude | President & CEO | S Sale | 2025-05-02 | 2025-05-05 | 4,834 | $6.84 | $33.1K | 2,348,313 | SEC↗ |
| Maraoui Claude | President & CEO | S Sale | 2025-03-11 | 2025-03-11 | 49,271 | $5.01 | $246.8K | 2,003,147 | SEC↗ |
| Maraoui Claude | President & CEO | S Sale | 2025-03-07 | 2025-03-10 | 14,905 | $5.01 | $74.7K | 2,052,418 | SEC↗ |
| Maraoui Claude | President & CEO | S Sale | 2025-03-06 | 2025-03-10 | 25,551 | $5.04 | $128.8K | 2,067,323 | SEC↗ |
| Maraoui Claude | President & CEO | S Sale | 2025-03-05 | 2025-03-05 | 18,147 | $5.13 | $93.1K | 2,092,874 | SEC↗ |
| Maraoui Claude | President & CEO | S Sale | 2025-03-04 | 2025-03-05 | 28,901 | $5.04 | $145.7K | 2,111,021 | SEC↗ |
| Maraoui Claude | President & CEO | S Sale | 2025-03-03 | 2025-03-05 | 23,508 | $5.19 | $122.0K | 2,139,922 | SEC↗ |
| Benesch Joseph | CFO | S Sale | 2025-02-21 | 2025-02-24 | 1,365 | $5.19 | $7.1K | 45,966 | SEC↗ |
| Benesch Joseph | CFO | S Sale | 2024-08-01 | 2024-08-01 | 9,324 | $5.47 | $51.0K | 47,331 | SEC↗ |
| Benesch Joseph | CFO | S Sale | 2024-07-23 | 2024-07-23 | 4,055 | $5.40 | $21.9K | 56,655 | SEC↗ |
| Pearce Michael Cooper | Director | A Award | 2024-07-19 | 2024-07-23 | 30,000 | — | $0 | 30,000 | SEC↗ |
| ROSENWALD LINDSAY A MD | Director | A Award | 2024-07-08 | 2024-07-10 | 9,728 | — | $0 | 153,973 | SEC↗ |
| Toledano Miranda Jayne | Director | A Award | 2024-07-08 | 2024-07-10 | 9,728 | — | $0 | 81,445 | SEC↗ |
| Herskowitz Neil | Director | A Award | 2024-07-08 | 2024-07-10 | 9,728 | — | $0 | 81,445 | SEC↗ |
| Smith Justin Adam | Director | A Award | 2024-07-08 | 2024-07-10 | 9,728 | — | $0 | 144,445 | SEC↗ |
| Benesch Joseph | CFO | A Award | 2024-05-01 | 2025-04-16 | 80,000 | — | $0 | 205,966 | SEC↗ |
| Maraoui Claude | President & CEO | A Award | 2024-05-01 | 2025-04-16 | 175,000 | — | $0 | 2,353,147 | SEC↗ |
| ROSENWALD LINDSAY A MD | Director | P Buy | 2024-03-25 | 2024-03-27 | 10,000 | $3.04 | $30.4K | 144,245 | SEC↗ |
| ROSENWALD LINDSAY A MD | Director | P Buy | 2024-03-22 | 2024-03-25 | 20,000 | $3.40 | $68.0K | 134,245 | SEC↗ |
| Smith Justin Adam | Director | P Buy | 2024-03-22 | 2024-03-25 | 30,000 | $3.47 | $104.1K | 134,717 | SEC↗ |
| Maraoui Claude | President & CEO | P Buy | 2024-03-22 | 2024-03-25 | 10,000 | $3.48 | $34.8K | 2,163,430 | SEC↗ |
| Benesch Joseph | Interim CFO | S Sale | 2024-02-22 | 2024-02-23 | 2,450 | $3.75 | $9.2K | 60,710 | SEC↗ |
| Benesch Joseph | CFO | A Award | 2024-01-03 | 2025-04-16 | 80,000 | — | $0 | 125,966 | SEC↗ |
| Maraoui Claude | President & CEO | A Award | 2024-01-03 | 2025-04-16 | 175,000 | — | $0 | 2,178,147 | SEC↗ |
| Paley Jeffrey | Director | S Sale | 2023-11-28 | 2023-11-29 | 1,745 | $5.22 | $9.1K | 70,727 | SEC↗ |
| Paley Jeffrey | Director | S Sale | 2023-11-08 | 2023-12-08 | 255 | $3.76 | $959 | 114,217 | SEC↗ |
| Paley Jeffrey | Director | S Sale | 2023-11-07 | 2023-12-08 | 2,245 | $3.48 | $7.8K | 114,472 | SEC↗ |
| Smith Justin Adam | Director | P Buy | 2023-10-13 | 2023-10-17 | 33,000 | $2.98 | $98.3K | 104,717 | SEC↗ |
| Paley Jeffrey | Director | P Buy | 2023-10-06 | 2023-10-10 | 15,000 | $2.98 | $44.7K | 72,472 | SEC↗ |
| Paley Jeffrey | Director | P Buy | 2023-09-21 | 2023-09-25 | 30,000 | $2.97 | $89.1K | 57,472 | SEC↗ |
| ROSENWALD LINDSAY A MD | Director | P Buy | 2023-09-06 | 2023-09-08 | 100,000 | $2.23 | $223.0K | 114,245 | SEC↗ |
| Maraoui Claude | President & CEO | P Buy | 2023-09-06 | 2023-09-08 | 26,044 | $2.52 | $65.6K | 2,153,430 | SEC↗ |
| Benesch Joseph | See Remarks | S Sale | 2023-07-24 | 2023-07-25 | 4,072 | $1.76 | $7.2K | 63,160 | SEC↗ |
| Maraoui Claude | President & CEO | S Sale | 2023-07-24 | 2023-07-25 | 20,767 | $1.76 | $36.5K | 2,127,386 | SEC↗ |
| Toledano Miranda Jayne | Director | A Award | 2023-07-21 | 2023-07-25 | 27,472 | — | $0 | 71,717 | SEC↗ |
| Smith Justin Adam | Director | A Award | 2023-07-21 | 2023-07-25 | 27,472 | — | $0 | 71,717 | SEC↗ |
| Paley Jeffrey | Director | A Award | 2023-07-21 | 2023-07-25 | 27,472 | — | $0 | 71,717 | SEC↗ |
| Herskowitz Neil | Director | A Award | 2023-07-21 | 2023-07-25 | 27,472 | — | $0 | 71,717 | SEC↗ |
| Maraoui Claude | President & CEO | S Sale | 2023-05-17 | 2023-05-18 | 24,377 | $1.34 | $32.7K | 2,148,153 | SEC↗ |
| Maraoui Claude | President & CEO | S Sale | 2023-05-16 | 2023-05-18 | 20,000 | $1.25 | $25.0K | 2,172,530 | SEC↗ |
| Fortress Biotech, Inc. | 10% Owner | J Other | 2023-05-12 | 2024-05-31 | 50,000 | — | $0 | 3,860,467 | SEC↗ |
| Benesch Joseph | Interim CFO | S Sale | 2023-02-22 | 2023-02-23 | 2,768 | $1.97 | $5.5K | 67,232 | SEC↗ |
| Fortress Biotech, Inc. | 10% Owner | J Other | 2023-02-12 | 2024-05-31 | 50,000 | — | $0 | 3,910,467 | SEC↗ |
| Fortress Biotech, Inc. | 10% Owner | J Other | 2022-11-12 | 2024-05-31 | 50,000 | — | $0 | 3,960,467 | SEC↗ |
| De Paolantonio Ernest Robert | See Remarks | S Sale | 2022-10-04 | 2023-03-01 | 10,093 | $2.41 | $24.3K | 259,907 | SEC↗ |
| De Paolantonio Ernest Robert | Chief Financial Officer | S Sale | 2022-10-04 | 2022-10-06 | 10,093 | $2.41 | $24.3K | 259,907 | SEC↗ |
| Fortress Biotech, Inc. | 10% Owner | J Other | 2022-08-12 | 2024-05-31 | 50,000 | — | $0 | 4,010,467 | SEC↗ |
| De Paolantonio Ernest Robert | Chief Financial Officer | A Award | 2022-07-21 | 2022-07-25 | 150,000 | — | $0 | 270,000 | SEC↗ |
| Maraoui Claude | President & CEO | A Award | 2022-07-21 | 2022-07-25 | 300,000 | — | $0 | 2,192,530 | SEC↗ |
| Toledano Miranda Jayne | Director | A Award | 2022-07-21 | 2022-07-25 | 14,245 | — | $0 | 44,245 | SEC↗ |
| Herskowitz Neil | Director | A Award | 2022-07-21 | 2022-07-25 | 14,245 | — | $0 | 44,245 | SEC↗ |
| Paley Jeffrey | Director | A Award | 2022-07-21 | 2022-07-25 | 14,245 | — | $0 | 44,245 | SEC↗ |
| Smith Justin Adam | Director | A Award | 2022-07-21 | 2022-07-25 | 14,245 | — | $0 | 44,245 | SEC↗ |
| ROSENWALD LINDSAY A MD | Director | A Award | 2022-07-21 | 2022-07-25 | 14,245 | — | $0 | 14,245 | SEC↗ |
| Fortress Biotech, Inc. | 10% Owner | J Other | 2022-05-12 | 2024-05-31 | 50,000 | — | $0 | 4,060,467 | SEC↗ |
| De Paolantonio Ernest Robert | Chief Financial Officer | A Award | 2022-01-14 | 2022-04-04 | 120,000 | — | $0 | 120,000 | SEC↗ |
| Herskowitz Neil | Director | A Award | 2022-01-14 | 2022-04-04 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Smith Justin Adam | Director | A Award | 2022-01-14 | 2022-04-04 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Paley Jeffrey | Director | A Award | 2022-01-14 | 2022-04-04 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Toledano Miranda Jayne | Director | A Award | 2022-01-14 | 2022-04-04 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 33,224 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 2,814 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 2,100 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 25,000 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 937 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 65,000 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 48,130 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 8,000 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 18,750 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 21,560 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 46,371 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 20,869 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 719 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer deriv | 2020-02-20 | 2020-02-24 | 87,990 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,378 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 25,000 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 2,437 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 88,251 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 32,506 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 71,397 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 17,062 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 50,178 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 60,000 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,000 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 65,000 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 63,750 | — | $0 | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 48,750 | — | $0 | 0 | SEC↗ |
| Cohen David E | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| Cohen David E | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| Cohen David E | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| Cohen David E | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,344 | — | $0 | 0 | SEC↗ |
| Cohen David E | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,344 | — | $0 | 0 | SEC↗ |
| Cohen David E | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 14,224 | — | $0 | 0 | SEC↗ |
| Cohen David E | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 8,620 | — | $0 | 0 | SEC↗ |
| Cohen David E | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 17,241 | — | $0 | 0 | SEC↗ |
| Cohen David E | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 3,000 | — | $0 | 0 | SEC↗ |
| Sebelius Kathleen | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| Sebelius Kathleen | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| Sebelius Kathleen | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,896 | — | $0 | 0 | SEC↗ |
| Sebelius Kathleen | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 20,689 | — | $0 | 0 | SEC↗ |
| Sebelius Kathleen | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 3,000 | — | $0 | 0 | SEC↗ |
| Sebelius Kathleen | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer deriv | 2020-02-20 | 2020-02-24 | 150,000 | — | $0 | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer deriv | 2020-02-20 | 2020-02-24 | 180,000 | — | $0 | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer deriv | 2020-02-20 | 2020-02-24 | 180,000 | — | $0 | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer deriv | 2020-02-20 | 2020-02-24 | 355,170 | — | $0 | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer deriv | 2020-02-20 | 2020-02-24 | 98,430 | — | $0 | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer deriv | 2020-02-20 | 2020-02-24 | 64,327 | — | $0 | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer deriv | 2020-02-20 | 2020-02-24 | 300,000 | — | $0 | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer deriv | 2020-02-20 | 2020-02-24 | 9,000 | — | $0 | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer deriv | 2020-02-20 | 2020-02-24 | 15,000 | — | $0 | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer deriv | 2020-02-20 | 2020-02-24 | 50,000 | — | $0 | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer deriv | 2020-02-20 | 2020-02-24 | 115,022 | — | $0 | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer deriv | 2020-02-20 | 2020-02-24 | 164,642 | — | $0 | 0 | SEC↗ |
| RINGO WILLIAM R | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| RINGO WILLIAM R | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| RINGO WILLIAM R | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 3,000 | — | $0 | 0 | SEC↗ |
| RINGO WILLIAM R | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 18,275 | — | $0 | 0 | SEC↗ |
| RINGO WILLIAM R | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 8,620 | — | $0 | 0 | SEC↗ |
| RINGO WILLIAM R | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,344 | — | $0 | 0 | SEC↗ |
| RINGO WILLIAM R | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| Gilbert Halley E | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 20,000 | — | $0 | 0 | SEC↗ |
| CRAVES FRED B | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| CRAVES FRED B | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| CRAVES FRED B | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| CRAVES FRED B | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 3,000 | — | $0 | 0 | SEC↗ |
| CRAVES FRED B | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,334 | — | $0 | 0 | SEC↗ |
| CRAVES FRED B | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,344 | — | $0 | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 2,437 | — | $0 | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 16,332 | — | $0 | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 103,258 | — | $0 | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 65,000 | — | $0 | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 57,000 | — | $0 | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 32,758 | — | $0 | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 110,434 | — | $0 | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 15,000 | — | $0 | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 5,700 | — | $0 | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 9,528 | — | $0 | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 52,500 | — | $0 | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 48,750 | — | $0 | 0 | SEC↗ |
| Horan Christopher | Chief Technical Ops Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 140,000 | — | $0 | 0 | SEC↗ |
| Horan Christopher | Chief Technical Ops Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 65,000 | — | $0 | 0 | SEC↗ |
| Horan Christopher | Chief Technical Ops Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 53,333 | — | $0 | 0 | SEC↗ |
| Horan Christopher | Chief Technical Ops Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer deriv | 2020-02-20 | 2020-02-24 | 7,040 | — | $0 | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer deriv | 2020-02-20 | 2020-02-24 | 708 | — | $0 | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer deriv | 2020-02-20 | 2020-02-24 | 67,500 | — | $0 | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer deriv | 2020-02-20 | 2020-02-24 | 2,814 | — | $0 | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer deriv | 2020-02-20 | 2020-02-24 | 574 | — | $0 | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,250 | — | $0 | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer deriv | 2020-02-20 | 2020-02-24 | 28,000 | — | $0 | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer deriv | 2020-02-20 | 2020-02-24 | 50,000 | — | $0 | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,000 | — | $0 | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer deriv | 2020-02-20 | 2020-02-24 | 22,500 | — | $0 | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer deriv | 2020-02-20 | 2020-02-24 | 11,500 | — | $0 | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer deriv | 2020-02-20 | 2020-02-24 | 28,130 | — | $0 | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| Lyons-Williams Lori | Chief Commercial Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 100,000 | — | $0 | 0 | SEC↗ |
| Lyons-Williams Lori | Chief Commercial Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,378 | — | $0 | 0 | SEC↗ |
| Lyons-Williams Lori | Chief Commercial Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 65,000 | — | $0 | 0 | SEC↗ |
| Lyons-Williams Lori | Chief Commercial Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 63,750 | — | $0 | 0 | SEC↗ |
| Lyons-Williams Lori | Chief Commercial Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Lyons-Williams Lori | Chief Commercial Officer | D To issuer deriv | 2020-02-20 | 2020-02-24 | 30,000 | — | $0 | 0 | SEC↗ |
| Fust Matthew K | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 14,224 | — | $0 | 0 | SEC↗ |
| Fust Matthew K | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,344 | — | $0 | 0 | SEC↗ |
| Fust Matthew K | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,344 | — | $0 | 0 | SEC↗ |
| Fust Matthew K | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| Fust Matthew K | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| Fust Matthew K | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 3,000 | — | $0 | 0 | SEC↗ |
| Fust Matthew K | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| MCDADE MARK | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| MCDADE MARK | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 23,275 | — | $0 | 0 | SEC↗ |
| MCDADE MARK | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 3,000 | — | $0 | 0 | SEC↗ |
| MCDADE MARK | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| MCDADE MARK | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| MCDADE MARK | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,344 | — | $0 | 0 | SEC↗ |
| MCDADE MARK | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 7,758 | — | $0 | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | D To issuer deriv | 2020-02-20 | 2020-02-24 | 73,287 | — | $0 | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | D To issuer deriv | 2020-02-20 | 2020-02-24 | 121 | — | $0 | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | D To issuer deriv | 2020-02-20 | 2020-02-24 | 67,240 | — | $0 | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | D To issuer deriv | 2020-02-20 | 2020-02-24 | 71,250 | — | $0 | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | D To issuer deriv | 2020-02-20 | 2020-02-24 | 71,250 | — | $0 | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | D To issuer deriv | 2020-02-20 | 2020-02-24 | 57,000 | — | $0 | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | D To issuer deriv | 2020-02-20 | 2020-02-24 | 65,000 | — | $0 | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | D To issuer deriv | 2020-02-20 | 2020-02-24 | 3,562 | — | $0 | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | D To issuer deriv | 2020-02-20 | 2020-02-24 | 5,700 | — | $0 | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | D To issuer deriv | 2020-02-20 | 2020-02-24 | 25,000 | — | $0 | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | D To issuer deriv | 2020-02-20 | 2020-02-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Nunn Jason Raleigh | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 3,000 | — | $0 | 0 | SEC↗ |
| Nunn Jason Raleigh | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| Nunn Jason Raleigh | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| Nunn Jason Raleigh | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,344 | — | $0 | 0 | SEC↗ |
| Nunn Jason Raleigh | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 10,334 | — | $0 | 0 | SEC↗ |
| Nunn Jason Raleigh | Director | D To issuer deriv | 2020-02-20 | 2020-02-24 | 6,000 | — | $0 | 0 | SEC↗ |
| ELI LILLY & Co | 10% Owner | P Buy | 2020-02-20 | 2020-02-20 | 40,926,025 | $18.75 | $767.36M | 100 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | D To issuer | 2020-02-20 | 2020-02-24 | 67,242 | $18.75 | $1.26M | 0 | SEC↗ |
| Pena Luis C. | Chief Development Officer | D To issuer | 2020-02-20 | 2020-02-24 | 18,233 | $18.75 | $341.9K | 0 | SEC↗ |
| Cohen David E | Director | D To issuer | 2020-02-20 | 2020-02-24 | 35,682 | $18.75 | $669.0K | 0 | SEC↗ |
| Sebelius Kathleen | Director | D To issuer | 2020-02-20 | 2020-02-24 | 6,000 | $18.75 | $112.5K | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer | 2020-02-20 | 2020-02-24 | 180,985 | $18.75 | $3.39M | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | D To issuer | 2020-02-20 | 2020-02-24 | 49,963 | $18.75 | $936.8K | 0 | SEC↗ |
| RINGO WILLIAM R | Director | D To issuer | 2020-02-20 | 2020-02-24 | 6,000 | $18.75 | $112.5K | 0 | SEC↗ |
| CRAVES FRED B | Director | D To issuer | 2020-02-20 | 2020-02-24 | 6,000 | $18.75 | $112.5K | 0 | SEC↗ |
| CRAVES FRED B | Director | D To issuer | 2020-02-20 | 2020-02-24 | 3,441,075 | $18.75 | $64.52M | 0 | SEC↗ |
| CRAVES FRED B | Director | D To issuer | 2020-02-20 | 2020-02-24 | 30,000 | $18.75 | $562.5K | 0 | SEC↗ |
| CRAVES FRED B | Director | D To issuer | 2020-02-20 | 2020-02-24 | 65,572 | $18.75 | $1.23M | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer | 2020-02-20 | 2020-02-24 | 3,726 | $18.75 | $69.9K | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | D To issuer | 2020-02-20 | 2020-02-24 | 16,206 | $18.75 | $303.9K | 0 | SEC↗ |
| Horan Christopher | Chief Technical Ops Officer | D To issuer | 2020-02-20 | 2020-02-24 | 21,400 | $18.75 | $401.3K | 0 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | D To issuer | 2020-02-20 | 2020-02-24 | 30,089 | $18.75 | $564.2K | 0 | SEC↗ |
| Lyons-Williams Lori | Chief Commercial Officer | D To issuer | 2020-02-20 | 2020-02-24 | 25,401 | $18.75 | $476.3K | 0 | SEC↗ |
| Fust Matthew K | Director | D To issuer | 2020-02-20 | 2020-02-24 | 5,051 | $18.75 | $94.7K | 0 | SEC↗ |
| MCDADE MARK | Director | D To issuer | 2020-02-20 | 2020-02-24 | 6,000 | $18.75 | $112.5K | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | D To issuer | 2020-02-20 | 2020-02-24 | 41,951 | $18.75 | $786.6K | 0 | SEC↗ |
| Nunn Jason Raleigh | Director | D To issuer | 2020-02-20 | 2020-02-24 | 6,000 | $18.75 | $112.5K | 0 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | G Gift | 2020-02-11 | 2020-02-24 | 12,924 | — | $0 | 3,726 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | G Gift | 2020-02-11 | 2020-02-24 | 10,772 | — | $0 | 16,206 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | G Gift | 2020-02-05 | 2020-02-24 | 27,000 | — | $0 | 49,963 | SEC↗ |
| Fust Matthew K | Director | S Sale | 2019-12-24 | 2019-12-26 | 3,000 | $15.00 | $45.0K | 5,051 | SEC↗ |
| Fust Matthew K | Director | S Sale | 2019-12-12 | 2019-12-13 | 3,000 | $12.00 | $36.0K | 8,051 | SEC↗ |
| Gilbert Halley E | Director | A Award deriv | 2019-11-11 | 2019-11-13 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | A Award deriv | 2019-11-11 | 2019-11-13 | 28,000 | — | $0 | 28,000 | SEC↗ |
| Aurora Daljit Singh | Chief Scientific Affairs Off | A Award deriv | 2019-11-11 | 2019-11-13 | 6,000 | — | $0 | 6,000 | SEC↗ |
| Fust Matthew K | Director | S Sale | 2019-09-12 | 2019-09-16 | 6,000 | $8.77 | $52.6K | 11,051 | SEC↗ |
| Pena Luis C. | Chief Development Officer | M Exercise deriv | 2019-08-19 | 2019-08-19 | 3,576 | — | $0 | 88,251 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | P Buy | 2019-08-19 | 2019-08-19 | 23,419 | $8.54 | $200.0K | 75,940 | SEC↗ |
| Pena Luis C. | Chief Development Officer | S Sale | 2019-08-19 | 2019-08-19 | 23,419 | $8.54 | $200.0K | 17,209 | SEC↗ |
| Pena Luis C. | Chief Development Officer | M Exercise | 2019-08-19 | 2019-08-19 | 3,576 | $0.99 | $3.5K | 40,628 | SEC↗ |
| GUGGENHIME ANDREW | CFO | M Exercise deriv | 2019-08-15 | 2019-08-19 | 3,562 | — | $0 | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | M Exercise deriv | 2019-08-15 | 2019-08-19 | 3,563 | — | $0 | 3,562 | SEC↗ |
| GUGGENHIME ANDREW | CFO | M Exercise deriv | 2019-08-15 | 2019-08-19 | 2,850 | — | $0 | 5,700 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | M Exercise deriv | 2019-08-15 | 2019-08-19 | 9,000 | — | $0 | 9,000 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | M Exercise deriv | 2019-08-15 | 2019-08-19 | 9,000 | — | $0 | 0 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | M Exercise deriv | 2019-08-15 | 2019-08-19 | 7,500 | — | $0 | 15,000 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | M Exercise deriv | 2019-08-15 | 2019-08-19 | 2,850 | — | $0 | 5,700 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | M Exercise deriv | 2019-08-15 | 2019-08-19 | 2,438 | — | $0 | 2,437 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | M Exercise deriv | 2019-08-15 | 2019-08-19 | 2,625 | — | $0 | 0 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | M Exercise deriv | 2019-08-15 | 2019-08-19 | 1,407 | — | $0 | 2,814 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | M Exercise deriv | 2019-08-15 | 2019-08-19 | 1,050 | — | $0 | 2,100 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | M Exercise deriv | 2019-08-15 | 2019-08-19 | 938 | — | $0 | 937 | SEC↗ |
| Griffith Christopher M. | Chief Business & Strategy Of | M Exercise deriv | 2019-08-15 | 2019-08-19 | 1,078 | — | $0 | 0 | SEC↗ |
| Lyons-Williams Lori | Chief Commercial Officer | M Exercise deriv | 2019-08-15 | 2019-08-19 | 3,189 | — | $0 | 6,378 | SEC↗ |
| Pena Luis C. | Chief Development Officer | M Exercise deriv | 2019-08-15 | 2019-08-19 | 3,189 | — | $0 | 6,378 | SEC↗ |
| Pena Luis C. | Chief Development Officer | M Exercise deriv | 2019-08-15 | 2019-08-19 | 2,438 | — | $0 | 2,437 | SEC↗ |
| Pena Luis C. | Chief Development Officer | M Exercise deriv | 2019-08-15 | 2019-08-19 | 3,000 | — | $0 | 0 | SEC↗ |
| GUGGENHIME ANDREW | CFO | F Tax w/h | 2019-08-15 | 2019-08-19 | 986 | $7.91 | $7.8K | 43,392 | SEC↗ |
| GUGGENHIME ANDREW | CFO | M Exercise | 2019-08-15 | 2019-08-19 | 2,850 | — | $0 | 37,253 | SEC↗ |
| GUGGENHIME ANDREW | CFO | M Exercise | 2019-08-15 | 2019-08-19 | 3,563 | — | $0 | 40,816 | SEC↗ |
| GUGGENHIME ANDREW | CFO | M Exercise | 2019-08-15 | 2019-08-19 | 3,562 | — | $0 | 44,378 | SEC↗ |
| GUGGENHIME ANDREW | CFO | F Tax w/h | 2019-08-15 | 2019-08-19 | 1,233 | $7.91 | $9.8K | 42,159 | SEC↗ |
| GUGGENHIME ANDREW | CFO | F Tax w/h | 2019-08-15 | 2019-08-19 | 1,232 | $7.91 | $9.7K | 40,927 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | M Exercise | 2019-08-15 | 2019-08-19 | 9,000 | — | $0 | 48,666 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | M Exercise | 2019-08-15 | 2019-08-19 | 7,500 | — | $0 | 65,166 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | M Exercise | 2019-08-15 | 2019-08-19 | 9,000 | — | $0 | 57,666 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | F Tax w/h | 2019-08-15 | 2019-08-19 | 3,719 | $7.91 | $29.4K | 52,521 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | F Tax w/h | 2019-08-15 | 2019-08-19 | 4,463 | $7.91 | $35.3K | 56,240 | SEC↗ |
| WIGGANS THOMAS G | CEO & Chairman of the Board | F Tax w/h | 2019-08-15 | 2019-08-19 | 4,463 | $7.91 | $35.3K | 60,703 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | F Tax w/h | 2019-08-15 | 2019-08-19 | 844 | $7.91 | $6.7K | 17,223 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | F Tax w/h | 2019-08-15 | 2019-08-19 | 986 | $7.91 | $7.8K | 15,329 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | F Tax w/h | 2019-08-15 | 2019-08-19 | 908 | $7.91 | $7.2K | 16,315 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | M Exercise | 2019-08-15 | 2019-08-19 | 2,438 | — | $0 | 12,592 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | M Exercise | 2019-08-15 | 2019-08-19 | 2,850 | — | $0 | 15,442 | SEC↗ |
| BAUER EUGENE A | Chief Medical Officer | M Exercise | 2019-08-15 | 2019-08-19 | 2,625 | — | $0 | 18,067 | SEC↗ |